Loading...
Chronic Pseudomonas aeruginosa infection is the leading cause of morbidity and mortality in patients with cystic fibrosis (CF). Aggressive antibiotic regimens have improved outcomes, but given the increase in antibiotic-resistant strains of P. aeruginosa, a vaccine that could prevent airway colonization with this pathogen could be highly beneficial. Investigators in Europe recently completed a multicenter phase III trial of such a vaccine.
These researchers randomized 483 CF patients not colonized with P. aeruginosa to receive four intramuscular doses of a bivalent P. aeruginosa flagella vaccine or placebo and followed them for 2 years for evidence of pseudomonas infection. Pseudomonas infections were significantly less common with the vacci…